Biotechnology - Biotechnology, Cardio-vascular

Filter

Popular Filters

1 to 25 of 111 results

Aegerion Pharma under SEC investigation

Aegerion Pharma under SEC investigation

14-01-2015

US biotech firm Aegerion Pharmaceuticals has revealed it is the subject of a US Securities and Exchange…

Aegerion PharmaceuticalsBiotechnologyBrazilCardio-vascularJuxtapidLegalMarkets & MarketingRare diseasesUSA

EMA accepts Sanofi and Regeneron's MMA for Praluent for review

EMA accepts Sanofi and Regeneron's MMA for Praluent for review

12-01-2015

French drug major Sanofi and US biotech company Regeneron have announced that the European Medicines…

alirocumabBiotechnologyCardio-vascularEuropeRegeneronRegulationSanofi

Sanofi and Regeneron’s alirocumab meets endpoints in cholesterol study

Sanofi and Regeneron’s alirocumab meets endpoints in cholesterol study

09-01-2015

French pharma major Sanofi and Regeneron Pharmaceuticals today announced that two new ODYSSEY trials,…

alirocumabBiotechnologyCardio-vascularRegeneron PharmaceuticalsResearchSanofi

X-Chem licenses second cardiovascular drug discovery program to Bayer

X-Chem licenses second cardiovascular drug discovery program to Bayer

18-12-2014

Privately-held biotech firm X-Chem has licensed a second drug discovery program to German pharma major…

BayerBiotechnologyCardio-vascularLicensingX-Chem

Kynamro achieves significant reduction in MACE

19-11-2014

A retrospective analysis has shown that patients treated with Kynamro (mipomersen sodium) injection for…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroResearchSanofi

Boehringer Ingelheim drops option for Athera’s PC-MAb

12-11-2014

Sweden’s Athera Biotechnologies, which is 65% owned by Karolinska Development, says that German family-owned…

Athera BiotechnologiesBiotechnologyBoehringer IngelheimCardio-vascularLicensing

Janssen and HemoShear identify vascular health benefits of RA drugs

Janssen and HemoShear identify vascular health benefits of RA drugs

11-11-2014

US biotech firm HemoShear and Janssen Research and Development plan to report data showing that a subset…

ActemraAnti-Arthritics/RheumaticsBiotechnologyCardio-vascularHemoShearJanssen Research and DevelopmentJohnson & JohnsonResearchRochesirukumabUSA

Celladon links with Lonza for commercial manufacturing of Mydicar

03-11-2014

Swiss chemical supplier Lonza and US biotech firm Celladon Corp have entered into an agreement providing…

BiotechnologyCardio-vascularCelladonFinancialLonzaProduction

Amgen sues Sanofi and Regeneron over alleged patent infringement

19-10-2014

USA-based Amgen has filed a law suit in the US District Court of Delaware against French pharma major…

alirocumabAmgenBiotechnologyCardio-vascularevolocumabLegalPatentsRegeneron PharmaceuticalsSanofiUSA

MedImmune and Shionogi sign license agreement for Shionogi's preclinical biologics in acute coronary syndrome

MedImmune and Shionogi sign license agreement for Shionogi's preclinical biologics in acute coronary syndrome

09-10-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

BiotechnologyCardio-vascularCrestorJapanLicensingMedImmuneShionogi

Cardio3 Biosciences gains preferred access to all Mayo Clinic regenerative medicine portfolio

Cardio3 Biosciences gains preferred access to all Mayo Clinic regenerative medicine portfolio

08-10-2014

Belgium biotech firm Cardio3 BioSciences says it has signed a preferred access agreement with the USA’s…

BelgiumBiotechnologyC-CureCardio-vascularCardio3 BioSciencesResearchUSA

EPIC Biotech conference: essential to prove comercial viability of propositions

EPIC Biotech conference: essential to prove comercial viability of propositions

03-10-2014

The key message from European Partnering and Investment Conference in biotech, held yesterday in London,…

Antibiotics and Infectious diseasesBiotechnologyBoehringer IngelheimCardio-vascularCNS DiseasesFinancialJohnson & JohnsonMerck SeronoOncologyResearch

Merck Serono to partner with Lupin for emerging market exposure

Merck Serono to partner with Lupin for emerging market exposure

17-09-2014

Merck Serono, the biotech unit of Germany’s Merck KGaA, has entered a strategic partnership with Indian…

Antibiotics and Infectious diseasesBiotechnologyCardio-vascularDiabetesGermanyIndiaLicensingLupinMerck KGaAMerck Serono

Strong Ph IIb results with Dezima’s CETP inhibitor TA-8995 in dyslipidemia

Strong Ph IIb results with Dezima’s CETP inhibitor TA-8995 in dyslipidemia

03-09-2014

Privately-held Dutch biotech firm Dezima Pharma says it has received very positive results in its Phase…

BiotechnologyCardio-vascularDEZ-001Dezima PharmaMitsubishi TanabeResearchTA-8995

Amgen files for EU approval of talimogene laherparepvec and for evolocumab

Amgen files for EU approval of talimogene laherparepvec and for evolocumab

02-09-2014

Leading independent biotech firm Amgen has submitted a Marketing Authorization Application to the European…

AmgenBiotechnologyCardio-vascularEuropeevolocumabFamilial hypercholesterolemiaHealthHealth Medical PharmaHealth Medical PharmaOncologyPCSK9Regulationtalimogene laherparepvec

Positive results from four pivotal alirocumab trials at ESC Congress

Positive results from four pivotal alirocumab trials at ESC Congress

31-08-2014

French pharma major Sanofi and US partner Regeneron Pharmaceuticals have announced detailed positive…

alirocumabBiotechnologyCardio-vascularRegeneron PharmaceuticalsResearchSanofi

Amgen files for US approval of cholesterol drug evolocumab

28-08-2014

USA-based Amgen, the world's leading independent biotech firm, has filed a Biologics License Application…

AmgenBiotechnologyCardio-vascularChemistryevolocumabFamilial hypercholesterolemiaHealth Medical PharmaHigh cholesterolPCSK9RegulationUSA

FDA priority review for Amgen’s ivabradine in CHF

FDA priority review for Amgen’s ivabradine in CHF

27-08-2014

The US Food and Drug Administration has granted priority review designation for US biotech giant Amgen’s…

AmgenBiotechnologyCardio-vascularivabradineRegulationServierUSA

Regado Biosciences permanently halts REGULATE-PCI trial

Regado Biosciences permanently halts REGULATE-PCI trial

25-08-2014

US-based cardiovascular specialist Regado Biosciences Regado Biosciences has announced the permanent…

BiotechnologyCardio-vascularRegadoResearchRevolixys

uniQure acquires cardiology gene therapy firm InoCard

12-08-2014

Netherlands-based human gene therapy firm uniQure says it has acquired Germany’s InoCard GmbH, an innovative,…

BiotechnologyCardio-vascularGermanyInoCardMergers & AcquisitionsNetherlandsuniQure

Amgen’s evolocumab to become gold standard among add-on statin therapies

Amgen’s evolocumab to become gold standard among add-on statin therapies

22-07-2014

Leading independent biotech firm Amgen’s investigational compound evolocumab (AMG-145) is set to become…

AmgenBiotechnologyCardio-vascularCardiovascular diseaseEuropeevolocumabMarkets & MarketingUSA

Regado Biosciences announces FDA’s clinical hold of Ph III trial

Regado Biosciences announces FDA’s clinical hold of Ph III trial

10-07-2014

The US Food and Drug Administration (FDA) has informed US-based cardiovascular specialist Regado Biosciences…

Acute coronary syndromeBiotechnologybivalirudinCardio-vascularMedicineRegadoRegulationUSA

AADi in-licenses Celgene’s ABI-009

20-05-2014

US clinical-stage biopharma company AADi says it has in-licensed ABI-009 from biotech firm Celgene. Financial…

AADiABI-009BiotechnologyCardio-vascularCelgeneOncologyRespiratory and Pulmonary

Evolocumab combined with statin results in further reduction of cholesterol levels

Evolocumab combined with statin results in further reduction of cholesterol levels

14-05-2014

Among patients with high cholesterol receiving moderate- or high-intensity statin therapy, the addition…

AmgenBiotechnologyCardio-vascularevolocumabResearch

1 to 25 of 111 results

Back to top